{"id":66382,"date":"2026-03-07T17:54:58","date_gmt":"2026-03-07T12:24:58","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=66382"},"modified":"2026-03-07T17:55:02","modified_gmt":"2026-03-07T12:25:02","slug":"the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/","title":{"rendered":"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/y0E1TdzRUo0?si=TUTkdsESYb3TsbNn\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">Managing the cardiotoxic effects of Anthracyclines (e.g., Doxorubicin) and Trastuzumab is a cornerstone of modern cardio-oncology. While both can lead to heart failure, their mechanisms and &#8220;reversibility&#8221; profiles differ significantly. Here is a clinical checklist for managing these toxicities.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">1. Baseline Assessment (Pre-Treatment)<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Before the first dose, establish a &#8220;cardiac starting point&#8221; to identify high-risk patients.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Imaging:<\/strong> Obtain a baseline <strong>Echo with Global Longitudinal Strain (GLS)<\/strong>. GLS is more sensitive than LVEF for detecting early subclinical injury.<\/li>\n\n\n\n<li class=\"\"><strong>Biomarkers:<\/strong> Measure baseline <strong>Troponin (I or T)<\/strong> and <strong>BNP\/NT-proBNP<\/strong>.<\/li>\n\n\n\n<li class=\"\"><strong>Risk Scoring:<\/strong> Calculate risk using the <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8019326\/\" type=\"link\" id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9065844\/\">HFA-ICOS assessment tool<\/a>, accounting for age, prior CVD, hypertension, and previous chest radiation. That is a tool by Cardio\u2010Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with International Cardio\u2010Oncology Society.<\/li>\n\n\n\n<li class=\"\"><strong>Optimization:<\/strong> Ensure BP is strictly controlled (target &lt;130\/80 mmHg) and start statins if the patient is high-risk.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">2. Monitoring During Therapy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The frequency of monitoring depends on the specific drug and the patient&#8217;s baseline risk.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Anthracyclines (Type I Toxicity &#8211; &#8220;Irreversible&#8221;)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Mechanism: Myocyte death and replacement fibrosis (often dose-dependent).<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Monitoring:<\/strong> Usually at baseline, at a <a href=\"https:\/\/academic.oup.com\/eurheartj\/article\/43\/41\/4229\/6673995?login=false\" type=\"link\" id=\"https:\/\/academic.oup.com\/eurheartj\/article\/43\/41\/4229\/6673995?login=false\">cumulative dose of 250 mg\/m<sup>2<\/sup><\/a>.<\/li>\n\n\n\n<li class=\"\"><strong>Red Flags:<\/strong> A drop in <strong>LVEF >10 percentage points<\/strong> to a value below <strong>50%<\/strong>, or a relative decrease in <strong>GLS >15%<\/strong> from baseline.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><a href=\"https:\/\/johnsonfrancis.org\/professional\/trastuzumab-and-cardiotoxicity\/\" type=\"link\" id=\"https:\/\/johnsonfrancis.org\/professional\/trastuzumab-and-cardiotoxicity\/\">Trastuzumab (Type II Toxicity &#8211; &#8220;Reversible&#8221;)<\/a><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Mechanism: Myocyte &#8220;stunning&#8221; or dysfunction without structural death.<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Monitoring:<\/strong> Typically every <strong>3 months<\/strong> during the one-year course of therapy.<\/li>\n\n\n\n<li class=\"\"><strong>Key Distinction:<\/strong> Unlike anthracyclines, trastuzumab toxicity is usually not dose-dependent and often improves after holding the medication.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">3. Intervention Thresholds<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">If toxicity is detected, the &#8220;Stop, Start, or Continue&#8221; decision is critical.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Clinical Finding<\/strong><\/td><td><strong>Action Plan<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Asymptomatic LVEF 40-49%<\/strong><\/td><td>Start ACEI\/ARB and Beta-blocker (Carvedilol preferred). Discuss &#8220;Treat-to-through&#8221; with Oncology.<\/td><\/tr><tr><td><strong>Symptomatic Heart Failure<\/strong><\/td><td><strong>Hold<\/strong> chemotherapy immediately. Initiate standard GDMT (Guideline-Directed Medical Therapy).<\/td><\/tr><tr><td><strong>\u0394 GLS decline >15% (Normal LVEF)<\/strong><\/td><td>Consider starting cardioprotective therapy (ACEI\/Statins) even if LVEF remains normal.<\/td><\/tr><tr><td><strong>Elevated Troponin<\/strong><\/td><td>Frequent monitoring; consider initiating ACEI to prevent LVEF decline.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">4. Post-Treatment Surveillance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Cardiotoxicity can manifest years after the conclusion of chemotherapy.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>High-Risk Patients:<\/strong> Echo at 6 months and 12 months post-treatment.<\/li>\n\n\n\n<li class=\"\"><strong>Long-term:<\/strong> Periodic screening every 1\u20135 years depending on the cumulative anthracycline dose and clinical status.<\/li>\n\n\n\n<li class=\"\"><strong>Lifestyle:<\/strong> Emphasize &#8220;heart-healthy&#8221; habits, as these survivors have a higher lifetime risk of CAD and metabolic syndrome.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Managing the cardiotoxic effects of Anthracyclines (e.g., Doxorubicin) and Trastuzumab is a cornerstone of modern cardio-oncology. While both can lead to heart failure, their mechanisms and &#8220;reversibility&#8221; profiles differ significantly. Here is a clinical checklist for managing these toxicities. 1. Baseline Assessment (Pre-Treatment) Before the first dose, establish a &#8220;cardiac starting point&#8221; to identify high-risk [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":66386,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-66382","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Managing the cardiotoxic effects of Anthracyclines (e.g., Doxorubicin) and Trastuzumab is a cornerstone of modern cardio-oncology. While both can lead to heart failure, their mechanisms and &#8220;reversibility&#8221; profiles differ significantly. Here is a clinical checklist for managing these toxicities. 1. Baseline Assessment (Pre-Treatment) Before the first dose, establish a &#8220;cardiac starting point&#8221; to identify high-risk [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-07T12:24:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-07T12:25:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/03\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1214\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity\",\"datePublished\":\"2026-03-07T12:24:58+00:00\",\"dateModified\":\"2026-03-07T12:25:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/\"},\"wordCount\":382,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/\",\"name\":\"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg\",\"datePublished\":\"2026-03-07T12:24:58+00:00\",\"dateModified\":\"2026-03-07T12:25:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg\",\"width\":1214,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/","og_locale":"en_US","og_type":"article","og_title":"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity - All About Cardiovascular System and Disorders","og_description":"Managing the cardiotoxic effects of Anthracyclines (e.g., Doxorubicin) and Trastuzumab is a cornerstone of modern cardio-oncology. While both can lead to heart failure, their mechanisms and &#8220;reversibility&#8221; profiles differ significantly. Here is a clinical checklist for managing these toxicities. 1. Baseline Assessment (Pre-Treatment) Before the first dose, establish a &#8220;cardiac starting point&#8221; to identify high-risk [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-03-07T12:24:58+00:00","article_modified_time":"2026-03-07T12:25:02+00:00","og_image":[{"width":1214,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/03\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity","datePublished":"2026-03-07T12:24:58+00:00","dateModified":"2026-03-07T12:25:02+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/"},"wordCount":382,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/03\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/","url":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/","name":"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/03\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg","datePublished":"2026-03-07T12:24:58+00:00","dateModified":"2026-03-07T12:25:02+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/03\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/03\/The-Cardio-Oncology-Checklist-Managing-Anthracycline-and-Trastuzumab-Toxicity-1.jpg","width":1214,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/the-cardio-oncology-checklist-managing-anthracycline-and-trastuzumab-toxicity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"The Cardio-Oncology Checklist: Managing Anthracycline and Trastuzumab Toxicity"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=66382"}],"version-history":[{"count":4,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66382\/revisions"}],"predecessor-version":[{"id":66388,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66382\/revisions\/66388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/66386"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=66382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=66382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=66382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}